Nebula turns the peer-reviewed literature into an interactive map of any technology, compound, or indication — so investment teams can see, in minutes, how much published science supports a start-up's claims.
A quick, visual read on the published evidence behind a deal — before the deep dive begins.
Type any technology, compound, or indication and Nebula pulls live publication data, then lays it out as an explorable 3D map.
Papers are automatically classified into eight disease areas and connected by topical relatedness, exposing where the evidence is — and isn't.
Every map is fully grounded in real papers — export the corpus as JSON or ZIP for your own diligence notes and models.
Consult Sciences Ltd provides scientific and technical consulting to biotech and life-science companies, investors, and research organizations. Our work spans literature and patent intelligence, scientific due diligence, and technical strategy.
Nebula is our first public product — a beta built to demonstrate the publication-intelligence work we do behind the scenes, packaged into a tool investment teams can use directly.
Nebula is currently in beta: fully functional, but still evolving. During the beta we are:
Request access below — beta participants get early access, priority feature input, and a free window into the paid release.
Tell us a little about you and how you'd use Nebula. We typically respond within two business days.
Fields marked * are required. Submitting opens your email client with a pre-filled request.
Prefer plain email? Write to [email protected]
Nebula visualizes published research as an evidence-mapping aid. It does not constitute investment, scientific, or legal advice. Beta contact: [email protected]